Alexion Pharmaceuticals
$159.379876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$159.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.87 (+1.18%) Today
-$0.36 (-0.23%) As of 11:49 AM UTC after-hours
Why Robinhood?
You can buy or sell ALXN and other stocks, options, and ETFs commission-free!
About ALXN
Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. The listed name for ALXN is Alexion Pharmaceuticals, Inc. Common Stock.
CEO
Ludwig N. Hantson
Employees
3,082
Headquarters
Boston, Massachusetts
Founded
1992
Market Cap
34.91B
Price-Earnings Ratio
37.33
Dividend Yield
—
Average Volume
3.74M
High Today
$160.33
Low Today
$158.01
Open Price
$158.35
Volume
2.79M
52 Week High
$160.33
52 Week Low
$72.67
Collections
Analyst Ratings
28%
of 18 ratings
Buy
28%
Hold
72%
Sell
0%
ALXN Earnings
$0.00
$1.08
$2.16
$3.24
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 4, Pre-Market